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Abstract 
 
Iran has had a peaceful nuclear program for more than 50 years, beginning with a research reactor purchased from the United 
States in 1959. There were a few suspicions of a nuclear weapons program, but these strongly abated in the decades after 
Iranian revolution in 1979. One of the most useful applications of nuclear energy in Iran is radionuclide imaging in sentinel 
lymph detection of breast cancer using Technetium (Tc) element. Sentinel lymph node is the first regional lymph node that 
drains the lymph from the primary tumor. It is potentially the first node to receive the seeding of lymph-borne metastatic cells. 
For sentinel node detection, one of the methods most often used in Iran is radionuclide imaging. However, guidelines strongly 
recommend imaging of the sentinel node combined with identification with a gamma probe before any operative procedure, 
rather than the use of external probe detection alone. In this regard, guidelines do not provide defined protocols for image 
acquisition and there is much controversy about the usefulness of dynamic imaging. This study aimed to discuss procedural 
guidelines for Lymphoscintigraphy for detection of sentinel node using 99mTc-Phytate in Isfahan, Iran.  
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1. Introduction  
 
Iran has had a peaceful nuclear program for more than 50 years, beginning with a research reactor purchased from the 
United States in 1959. The Iran first plan to build 23 nuclear power reactors by the 1990s was regarded as grandiose, but 
not necessarily viewed as a “back door” to a nuclear weapons program, possibly because Iran did not then seek the 
technologies to enrich or reprocess its own fuel. There were a few suspicions of a nuclear weapons program, but these 
strongly abated in the decades after Iranian revolution [1]. One of the most useful applications of nuclear energy in Iran is 
radionuclide imaging in detection of breast cancer using Technetium (Tc) element. In this regard, sentinel lymph node is 
the first regional lymph node that drains the lymph from the primary tumor. It is potentially the first node to receive the 
seeding of lymph-borne metastatic cells [2]. The presence or absence of metastasis to locoregional lymph nodes, 
especially axillary nodes, has major prognostic and therapeutic implications for patients with breast cancer [3-5]. There is 
ample evidence that a tumor negative sentinel lymph node is a reliable predictor for the absence of tumor invasion in 
other lymph nodes [3, 6].  
Lymphoscintigraphy [7] allows the surgeon to easily identify and biopsy the sentinel lymph node. This method 
identifies the sentinel node but cannot determine if it is involved with cancer [8].  
There are different approaches; however, guidelines strongly recommend imaging of the sentinel node combined 
with identification with a gamma probe before any operative procedure, rather than the use of external probe detection 
alone. The first ‘hot spot’ detected on images has to be considered the sentinel node [9-11]. Imaging also offers the ability 
to identify different pathways of lymphatic drainage from the tumor, resulting in the detection of more and extra-axillary 
sentinel nodes [12].  
Generally it is stated that static images should be taken hours after injection (2–18 h) [10]. The Society of Nuclear 
Medicine has no specific guidelines on sentinel node procedures.  
Because of the low visualization rate of sentinel nodes on dynamic imaging during the 30 min after injection, we 
ISSN 2039-2117 (online) 
ISSN 2039-9340 (print) 
        Mediterranean Journal of Social Sciences 
            MCSER Publishing, Rome-Italy 
Vol 6 No 1 S1 
January  2015 
          
 644 
changed our protocol [13-16]. In March 2013 we started our current protocol, in which static images are acquired 5, 30 
and 120 min after injection. This study aimed to discuss procedural guidelines for Lymphoscintigraphy for detection of 
sentinel node using 99mTc-Phytate in Isfahan, Iran. 
 
2. Procedural Guidelines 
 
General guidelines are in accordance with those previously reported by EANM [10]. EANM has written and approved 
these guidelines to promote the cost-effective use of high-quality nuclear medicine procedures. Therefore in this section, 
the approved guidelines by EANM are presented accordingly [10]. 
A variety of colloids have been used in this technique. The radiopharmaceuticals commonly employed for LS are 
99mTc-sulphur colloid (particles’ size: 15–5,000 nm), 99mTc-nanocolloid (5–100 nm), 99mTc-antimony trisulphide (3–30 nm). 
The choice of the radiopharmaceutical depends on the geographic area: in Europe, 99mTc-nanocolloid; in USA, 99mTc-
sulphur colloid; and in Canada and Australia, 99mTc-antimony trisulphide [17, 18]. In our center, we use 0.5 to 1 mCi of 
99mTc-Phytate. 
There is a general agreement that a radiocolloid with the majority of particles ranging between 100 and 200 nm in 
size can be considered the best compromise between fast lymphatic drainage and optimal retention in the sentinel lymph 
node [17, 18]. 
If a single node wishes to be seen and imaging times cannot be coordinated with the operating theatre time, a 
large colloid with a size of 200–1,000 nm is recommended [7, 9, 19]. It has been found that these larger colloids tend to 
“stick” in the sentinel node and allow imaging for up to 20 h post injection. 
The SN is, generally, visualized in 2 h, and the patient should be in the operating theatre within about 16–20 h after 
the injection of the colloid [2, 5, 8, 11, 18]. The colloid must be labelled with technetium pertechnetate using 
manufacturer’s instructions. A labelling yield greater than 95% must be assessed before injecting the 
radiopharmaceutical. General radiopharmaceutical requirements for quality control must be used [18, 20]. 
Large volumes of colloid may disrupt local lymphatics; therefore, small volumes should be injected [8, 21]. A single 
aliquot of 5–20 MBq (depending on the elapsed time between scintigraphy and surgery) of colloid in 0.2 ml is considered 
sufficient. A higher activity can be used for late procedures. The syringe should also contain a similar amount of air to 
clear any dead space within the syringe and the needle. In deep lesions, a slightly larger volume (0.5 ml) may be used. 
Two type of injection are widely used for this method. A sub-dermal injection over the tumor site is sufficient for all 
but the deepest tumors [8, 21]. The site of injection can be gently massaged after the administration or if passage of 
activity from the injection site is delayed at any time during the study. A peri-tumoral injection of 0.5 ml is recommended in 
all deep tumors [21, 22]. If the lump is not palpable, ultrasound can be used to guide the injection. 
Peri-areolar injection can be used particularly in upperquadrant tumors to avoid possible cross-talk due to short 
distance between peri-tumoral depot and the axillary sentinel node [22, 23]. This technique has the advantage of 
demanding less experience, particularly in non-palpable lesions. At present there is no evidence to justify intratumoral 
injections of colloids. 
Imaging is strongly recommended before any operative procedure [24, 25], as there is some variability in breast 
lymphatic drainage into the axilla and more than one sentinel node can be visualised in up to 20% of patients. 
 
3. Lymphoscintigraphy for Detection of Sentinel Node in our Center 
 
Lymphoscintigraphy for detection of sentinel node in our center is included intra-dermal injection of 0.5 to 1 mCi of 99mTc-
Phytate. Then, 5, 30 and 120 minute hands up lymphoscintigraphy is performed. All images in this center are acquired 
using Gamma camera (energy 140 keV, window 15–20% and LEHR collimator). For all patients, the scintigraphic images 
are retrospectively evaluated. All hot spots are noted and classified according to anatomic location and designated as 
sentinel node or higher echelon node.  
The evaluation is carried out by one nuclear medicine physician and one trainee in nuclear medicine, both 
experienced in sentinel node procedures. Where there are different interpretations, a consensus will be found [26]. All 
surgical and pathologic reports are retrospectively screened to score the number of nodes removed, the histology of the 
primary tumor, the presence of malignant cells in the sentinel node, the number of axillary lymph node dissections 
(ALND) and to determine whether malignancy was present in the nodes after ALND. 
Report of the first year's clinical experience of 99mTc-Phytate lymphoscintigraphy for detection of sentinel node 
using the above mentioned protocol is under preparation.  
The gamma camera used for lymphoscintigraphy in our center is equipped with a low-energy, high-resolution 
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collimator. The energy window is 15% (±5%) centered over the 140 keV photopeak of 99mTc. 
To position the patient, the patient lies supine with hands up for imaging on the gamma-camera bed. Anterior and 
45° anterior oblique imaging should be obtained. It is useful if the arm on the side of the cancer is extended laterally to 
90°, as this will be the position during surgery. 
In this protocol, truncation of the high-activities (injection site) will improve visualization of the sentinel node. A 
logarithmic scale to enhance low-count areas instead of a linear scale is preferable for image display [7]. 
The rest of process of this protocol is listed as bellow: 
 
3.1 Reporting 
 
The report to the referring physician should describe: 
• Site of image acquisition (projections of breast and axilla) 
• Radiopharmaceutical, way of administration, and amount of activity injected 
• Location of the sentinel node(s) on gamma-camera images 
• Any source of error or inaccuracy of the procedure 
 
3.2 Sources of error 
 
As the rate of passage of the smaller colloids is variable, it is advisable that frequent or continuous measurement is 
performed to identify when activity has reached the sentinel node and determine when intra-operative probing will be 
optimal. 
 
3.3 Issues requiring further clarification 
 
• Even if some authors consider that the previous breast biopsy can alter the lymphatic drainage affecting the 
results of sentinel node biopsy, there are other evidences that sentinel node biopsy performed in the area of 
previous breast biopsy do not affect the accuracy of the procedure [4, 27]. 
• There is still an open discussion on the influence of neo-adjuvant chemotherapy on sentinel node identification 
and removal [4, 27]. 
• Multiple foci of carcinoma, particularly when located in different quadrants, have been considered a relative 
contraindication for sentinel lymph node biopsy because of concerns that these tumors involve more than one 
lymphatic vessel. Recent studies report that sentinel node localisation maintain its negative predictive value 
also in patients with multicentric and multifocal breast carcinoma [7, 18, 22]. 
• Though there is some evidence that peri-areolar injection will be effective in patients with suspected multifocal 
or multicentric lesions, this must be confirmed by larger trials [27, 28]. 
• There is no definitive consensus on what to do if the sentinel node cannot be visualized. 
 
4. Discussion 
 
Iran started peaceful utilization of nuclear energy many years ago. In this regard, Iran has asserted repeatedly that its 
nuclear program is strictly peaceful, stating in May 2003 that “we consider the acquiring, development and use of nuclear 
weapons inhuman, immoral, illegal and against our basic principles. They have no place in Iran’s defense doctrine. [29]” 
Iranian officials have also insisted on their right to develop peaceful uses of nuclear technology. Former President 
Khatami stated in March 2005 that ending Iran’s uranium enrichment program is “completely unacceptable,” but that Iran 
would provide “objective guarantees” of the peaceful uses of enrichment. Nuclear energy can be used for both peaceful 
(medical applications) and military (nuclear weapons) uses. In Iran, one of the most useful applications of nuclear energy 
is radionuclide imaging in sentinel node detection of breast cancer using Technetium (Tc) element. 
According to the definition, the sentinel node is the first draining lymph node on the direct pathway from the primary 
tumor site [27, 28]. This is a good argument for dynamic imaging directly after injection because it provides the possibility 
of detecting the ‘real’ sentinel node. However, this definition is not always applicable during surgery for practical 
considerations. Therefore, guidelines usually provide more practical definitions for pointing out the sentinel node with the 
gamma probe during surgery. The EANM guideline proposes that the surgeon must locate the lymph node with the 
highest activity guided by the skin mark based on the scintigraphic images and the gamma probe. When there are two or 
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more of such lymph nodes, all should be removed [17, 23]. 
The Dutch guideline states that, after excision of the most active lymph node, the wound should be measured for 
high residual activity. If this activity exceeds 10% of the total activity in the removed lymph node, the surgeon must search 
for other active nodes and these must be removed as well [10, 19]. Both of those recommendations do not take into 
account the anatomic basis of the sentinel node principle. Because of this discrepancy between theoretical and practical 
definitions, a less active node, first draining on the pathway from the tumor, may be left in situ, thereby strongly reducing 
the added value of dynamic imaging directly after injection. 
The EANM guidelines give no strong recommendations for the site of injection, and the volumes suggested differ 
depending on the site of injection. There are three major differences in our protocol compared with the EANM guidelines: 
we administered a radioactive dose of 0.5 to 1 mCi and in all the patients, after intra-dermal injection of 0.5 to 1 mCi of 
99mTc-Phytate, 5, 30 and 120 minute hands up lymphoscintigraphy was performed. 
There is no assumption that a relatively high activity would have effect on the time point of sentinel node 
visualization. It has been suggested that administration of a larger quantity of nanocolloid would result in higher 
extractions from the injected site and higher accumulations in the lymph nodes [11, 18, 21, 22]. In some centers the most 
active node and the node closest to the tumor in the axillary region and the parasternal region are classified as sentinel 
nodes [10, 19]. When lymph vessels are visible, the first node in the chain and the most active node are called sentinel 
nodes.  
Considering optimal patient care [30], one could propose scanning every patient 30 min after injection, allowing the 
patient to be operated upon faster. In our experience operating schedules allow the patient to be operated upon earlier in 
the day, except for the first patient of the day to undergo surgery. However, in certain circumstances it may be helpful to 
speed up the procedures at the nuclear medicine department, considering a chance of visualization in 5 min. 
 
5. Conclusion 
 
In this study, procedural guidelines for Lymphoscintigraphy detection of sentinel node using 99mTc-Phytate in Iran were 
thought. Compared to other centers, guidelines provide defined protocols for image acquisition. 
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